Role of DAT‐SPECT in the diagnostic work up of Parkinsonism

The diagnosis of idiopathic Parkinson's disease (PD) can be achieved with high degrees of accuracy in cases with full expression of classical clinical features. However, diagnostic uncertainty remains in early disease with subtle or ambiguous signs. Functional imaging has been suggested to increase the diagnostic yield in parkinsonian syndromes with uncertain clinical classification. Loss of striatal dopamine nerve terminal function, a hallmark of neurodegenerative Parkinsonism, is strongly related to decreases of dopamine transporter (DAT) density, which can be measured by single photon emission computed tomography (SPECT). The use of DAT‐SPECT facilitates the differential diagnosis in patients with isolated tremor symptoms not fulfilling PD or essential tremor criteria, drug‐induced, psychogenic and vascular Parkinsonism as well as dementia when associated with Parkinsonism. This review addresses the value of DAT‐SPECT in early differential diagnosis, and its potential as a screening tool for subjects at risk of developing PD as well as issues around the assessment of disease progression. © 2007 Movement Disorder Society

[1]  H. Berendse,et al.  Idiopathic hyposmia as a preclinical sign of Parkinson's disease , 2004, Annals of neurology.

[2]  Klaus Seppi,et al.  Topography of dopamine transporter availability in progressive supranuclear palsy: a voxelwise [123I]beta-CIT SPECT analysis. , 2006, Archives of neurology.

[3]  S. Gacinovic,et al.  Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]‐FP‐CIT SPECT imaging: The [123I]‐FP‐CIT study group , 2000, Movement disorders : official journal of the Movement Disorder Society.

[4]  M. Critchley,et al.  Arteriosclerotic Parkinsonism , 1930, Edinburgh medical journal.

[5]  I. Podreka,et al.  β-CIT SPECT demonstrates blockade of 5HT-uptake sites by citalopram in the human brain in vivo , 2005, Journal of Neural Transmission / General Section JNT.

[6]  David J Brooks,et al.  Imaging end points for monitoring neuroprotection in Parkinson's disease , 2003, Annals of neurology.

[7]  Thomas Hummel,et al.  Detection of presymptomatic Parkinson's disease: Combining smell tests, transcranial sonography, and SPECT , 2004, Movement disorders : official journal of the Movement Disorder Society.

[8]  P. Thompson,et al.  Isolated tremor and disruption of the nigrostriatal dopaminergic system , 1992, Neurology.

[9]  Eileen O. Smith,et al.  Decreased single‐photon emission computed tomographic {123I}β‐CIT striatal uptake correlates with symptom severity in parkinson's disease , 1995, Annals of neurology.

[10]  M. Lakie,et al.  A study of the early signs of drug induced parkinsonism. , 1993, Journal of neurology, neurosurgery, and psychiatry.

[11]  K. Jellinger.  Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies , 2004, Neurology.

[12]  A. Lang,et al.  Psychogenic movement disorders , 2009, Current opinion in neurology.

[13]  J S Rakshi,et al.  Measuring the rate of progression and estimating the preclinical period of Parkinson’s disease with [18F]dopa PET , 1998, Journal of neurology, neurosurgery, and psychiatry.

[14]  G. Uhl,et al.  Phosphatidylinositol 3-Kinase, Protein Kinase C, and MEK1/2 Kinase Regulation of Dopamine Transporters (DAT) Require N-terminal DAT Phosphoacceptor Sites* , 2003, Journal of Biological Chemistry.

[15]  D. Mash,et al.  Dopaminergic innervation of the human striatum in Parkinson's disease , 2007, Movement disorders : official journal of the Movement Disorder Society.

[16]  J. Seibyl,et al.  Effect of treatment with L‐dopa/carbidopa or L‐selegiline on striatal dopamine transporter SPECT imaging with [123I]β‐CIT , 1999, Movement disorders : official journal of the Movement Disorder Society.

[17]  I. McKeith,et al.  Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease , 2004, Neurology.

[18]  T. Yen,et al.  Differential diagnosis of Parkinson's disease and vascular parkinsonism by (99m)Tc-TRODAT-1. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[19]  O. Pogarell,et al.  Striatal dopamine transporter binding in early to moderately advanced Parkinson's disease: monitoring of disease progression over 2 years , 2001, Nuclear medicine communications.

[20]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[21]  L. Deecke,et al.  [123I]β‐CIT spect in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration , 2000, Movement disorders : official journal of the Movement Disorder Society.

[22]  Willibald Gerschlager,et al.  Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: A longitudinal β‐CIT SPECT study , 2002, Movement disorders : official journal of the Movement Disorder Society.

[23]  H. Berendse,et al.  Subclinical dopaminergic dysfunction in asymptomatic Parkinson's disease patients' relatives with a decreased sense of smell , 2001, Annals of neurology.

[24]  D. Brooks,et al.  Long duration asymmetrical postural tremor is likely to predict development of Parkinson’s disease and not essential tremor: clinical follow up study of 13 cases , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[25]  W. Gibb,et al.  The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. , 1988, Journal of neurology, neurosurgery, and psychiatry.

[26]  M. Onofrj,et al.  Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium , 2006, Neurology.

[27]  K. Jellinger,et al.  Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. , 1996, Neurology.

[28]  Robert B. Innis,et al.  [123I]β‐CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson's disease and multiple system atrophy , 2001 .

[29]  A. Kessels,et al.  Meta-analysis of the literature on diagnostic accuracy of SPECT in parkinsonian syndromes , 2007, BMC neurology.

[30]  Walter Paulus,et al.  Dyskinesias due to intravenous apomorphine abuse in a patient without basal ganglia disorder , 2005, Movement disorders : official journal of the Movement Disorder Society.

[31]  S Fahn,et al.  Tolcapone , 1998, Neurology.

[32]  J. Seibyl,et al.  [123I]β-CIT SPECT imaging assessment of the rate of Parkinson’s disease progression , 2001, Neurology.

[33]  J. Penney,et al.  Regional dopamine transporter gene expression in the substantia nigra from control and Parkinson’s disease brains , 1998, Journal of neurology, neurosurgery, and psychiatry.

[34]  Claude Nahmias,et al.  Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET study , 2003, Annals of neurology.

[35]  Thomas Behr,et al.  Dopamine transporter imaging and SPECT in diagnostic work‐up of Parkinson's disease: A decision‐analytic approach , 2003, Movement disorders : official journal of the Movement Disorder Society.

[36]  John Seibyl,et al.  Dopamine agonists and Parkinson's disease progression: What can we learn from neuroimaging studies , 2003, Annals of neurology.

[37]  P B Hoffer,et al.  Test/retest reproducibility of iodine-123-betaCIT SPECT brain measurement of dopamine transporters in Parkinson's patients. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[38]  E. Tolosa,et al.  Transient arrest of psychogenic tremor induced by contralateral ballistic movements , 2004, Neuroscience Letters.

[39]  G. Wooten.  Agonists vs levodopa in PD: The thrilla of whitha , 2003 .

[40]  Lee-Tzuu Chang,et al.  A Method for Attenuation Correction in Radionuclide Computed Tomography , 1978, IEEE Transactions on Nuclear Science.

[41]  E. Tolosa,et al.  Impact of dopamine transporter SPECT using 123I‐Ioflupane on diagnosis and management of patients with clinically uncertain parkinsonian syndromes , 2004, Movement disorders : official journal of the Movement Disorder Society.

[42]  Jan Booij,et al.  The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism , 2001, European Journal of Nuclear Medicine.

[43]  J. C. Stoof,et al.  Drug-naive patients with Parkinson’s disease in Hoehn and Yahr stages I and II show a bilateral decrease in striatal dopamine transporters as revealed by [123I]β-CIT SPECT , 1997, Journal of Neurology.

[44]  W. Koch,et al.  Loss of dopamine transporter binding in Parkinson's disease follows a single exponential rather than linear decline. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[45]  Kazuto Yoshida,et al.  Brain 3D-SSP SPECT analysis in dementia with Lewy bodies, Parkinson's disease with and without dementia, and Alzheimer's disease , 2005, Clinical Neurology and Neurosurgery.

[46]  P. Hobson,et al.  Accuracy of diagnosis in patients with presumed Parkinson's disease. , 1999, Age and ageing.

[47]  E. Tolosa,et al.  123I‐Ioflupane SPECT in the diagnosis of suspected psychogenic Parkinsonism , 2006, Movement disorders : official journal of the Movement Disorder Society.

[48]  J S Fowler,et al.  Mechanism of action of methylphenidate: Insights from PET imaging studies , 2002, Journal of attention disorders.

[49]  A. Lees,et al.  Ageing and Parkinson's disease: substantia nigra regional selectivity. , 1991, Brain : a journal of neurology.

[50]  P. Tienari,et al.  How useful is [123I]β-CIT SPECT in clinical practice? , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[51]  S. Asenbaum,et al.  [123I]β-CIT and SPECT in essential tremor and Parkinson's disease , 1998, Journal of Neural Transmission.

[52]  G. Wenning,et al.  Multiple system atrophy: An update , 2003, Movement disorders : official journal of the Movement Disorder Society.

[53]  A. Rajput,et al.  Anomalies of asymmetry of clinical signs in parkinsonism , 2004, Movement disorders : official journal of the Movement Disorder Society.

[54]  L. Forno.  Reaction of the substantia nigra to massive basal ganglia infarction , 2004, Acta Neuropathologica.

[55]  J. Seibyl,et al.  Hemi‐parkinsonism due to a midbrain arteriovenous malformation: dopamine transporter imaging , 2001, Movement disorders : official journal of the Movement Disorder Society.

[56]  B. Bloem,et al.  [123I]β‐CIT SPECT distinguishes vascular parkinsonism from Parkinson's disease , 2002, Movement disorders : official journal of the Movement Disorder Society.

[57]  H. Panitch,et al.  Treatment of steroid-unresponsive tumefactive demyelinating disease with plasma exchange. , 2002, Neurology.

[58]  J. Jankovic.  Essential tremor course and disability: A clinicopathologic study of 20 cases , 2004, Neurology.

[59]  Yoav Ben-Shlomo,et al.  The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. , 2002, Brain : a journal of neurology.

[60]  R. Djaldetti,et al.  123I-FP-CIT SPECT imaging of dopamine transporters in patients with cerebrovascular disease and clinical diagnosis of vascular parkinsonism. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[61]  J. Javitch,et al.  N-Terminal Phosphorylation of the Dopamine Transporter Is Required for Amphetamine-Induced Efflux , 2004, PLoS biology.

[62]  P. Morrish.  How valid is dopamine transporter imaging as a surrogate marker in research trials in Parkinson's disease? , 2003, Movement disorders : official journal of the Movement Disorder Society.

[63]  I. Podreka,et al.  Measurement of the dopaminergic degeneration in Parkinson’s disease with [123I]β-CIT and SPECT , 1997 .

[64]  J. Javitch,et al.  Akt Is Essential for Insulin Modulation of Amphetamine-Induced Human Dopamine Transporter Cell-Surface Redistribution , 2005, Molecular Pharmacology.

[65]  J. Jolles,et al.  Methylphenidate down-regulates the dopamine receptor and transporter system in children with attention deficit hyperkinetic disorder (ADHD). , 2003, Neuropediatrics.

[66]  W. Oertel,et al.  Combination of 'idiopathic' REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. , 2004, Brain : a journal of neurology.

[67]  A. Cagnin,et al.  Thiethylperazine‐induced parkinsonism: in vivo demonstration of dopamine D2 receptors blockade , 2004, European journal of neurology.

[68]  D Oakes,et al.  Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease , 2003, Experimental Neurology.

[69]  L. Thal,et al.  What best differentiates Lewy body from Alzheimer's disease in early-stage dementia? , 2006, Brain : a journal of neurology.

[70]  J. Sundsfjord,et al.  123I-β-CIT SPECT demonstrates increased presynaptic dopamine transporter binding sites in basal ganglia in vivo in schizophrenia , 2004, Psychopharmacology.

[71]  Stephen A. Williams,et al.  Changes in Human In vivo Serotonin and Dopamine Transporter Availabilities during Chronic Antidepressant Administration , 2003, Neuropsychopharmacology.

[72]  I. McKeith,et al.  Progression of dopaminergic degeneration in dementia with Lewy bodies and Parkinson’s disease with and without dementia assessed using 123I-FP-CIT SPECT , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[73]  C. Katona,et al.  In-vivo demonstration of dopaminergic degeneration in dementia with Lewy bodies , 1999, The Lancet.

[74]  S. Asenbaum,et al.  Measurement of the dopaminergic degeneration in Parkinson's disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. , 1997, Journal of neural transmission. Supplementum.

[75]  E. Montgomery,et al.  Slowing Parkinson’s disease progression: Recent dopamine agonist trials , 2004, Neurology.

[76]  Klaus Seppi,et al.  Voxel-wise analysis of [123I]beta-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson's disease. , 2005, Brain : a journal of neurology.

[77]  Andrew J. Lees,et al.  Improved accuracy of clinical diagnosis of Lewy body Parkinson’s disease , 2001, Neurology.

[78]  L. Deecke,et al.  Imaging of dopamine transporters with iodine-123-beta-CIT and SPECT in Parkinson's disease. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[79]  Christian Kolbitsch,et al.  Evaluation of Striatal Dopamine Transporter Function in Rats by in Vivo β-[123I]CIT Pinhole SPECT , 2002, NeuroImage.

[80]  D. Grosset,et al.  The role of radiotracer imaging in Parkinson disease , 2005, Neurology.

[81]  B Bioulac,et al.  Relationship between the Appearance of Symptoms and the Level of Nigrostriatal Degeneration in a Progressive 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Lesioned Macaque Model of Parkinson's Disease , 2001, The Journal of Neuroscience.

[82]  J. Jankovic,et al.  The evolution of diagnosis in early Parkinson disease. Parkinson Study Group. , 2000, Archives of neurology.

[83]  J B Habraken,et al.  Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[84]  M. Canesi,et al.  123I-Ioflupane/SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy , 2003, Neurological Sciences.

[85]  David Oakes,et al.  (123I) beta-CIT and single-photon emission computed tomographic imaging vs clinical evaluation in Parkinsonian syndrome: unmasking an early diagnosis. , 2004, Archives of neurology.

[86]  J. Unterrainer,et al.  Measuring the progression of idiopathic Parkinson's disease with [123I] β-CIT SPECT , 2000, Journal of Neural Transmission.

[87]  Werner H. Mess,et al.  Diagnostic Value of 123I-Ioflupane and 123I-Iodobenzamide SPECT Scans in 248 Patients with Parkinsonian Syndromes , 2008, European Neurology.

[88]  Andrew J Lees,et al.  Clinicopathological investigation of vascular parkinsonism, including clinical criteria for diagnosis , 2004, Movement disorders : official journal of the Movement Disorder Society.

[89]  S. Fahn,et al.  Phenomenology and psychopathology related to psychogenic movement disorders. , 1995, Advances in neurology.

[90]  H. Melikian,et al.  Membrane Trafficking Regulates the Activity of the Human Dopamine Transporter , 1999, The Journal of Neuroscience.

[91]  S. Asenbaum,et al.  [123I]beta-CIT and SPECT in essential tremor and Parkinson's disease. , 1998, Journal of neural transmission.

[92]  J. P. Seibyl,et al.  [sup 123 I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease , 1996, Neurology.

[93]  C. Katona,et al.  Dementia with Lewy bodies: a study of post-synaptic dopaminergic receptors with iodine-123 iodobenzamide single-photon mission tomography , 1997, European Journal of Nuclear Medicine.

[94]  D. Linszen,et al.  Dopamine transporter density in young patients with schizophrenia assessed with [123]FP-CIT SPECT , 2001, Schizophrenia Research.

[95]  Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. , 2002, JAMA.

[96]  I. McKeith,et al.  Longitudinal study of cerebral blood flow SPECT in Parkinson's disease with dementia, and dementia with Lewy bodies , 2005, International journal of geriatric psychiatry.

[97]  S. Gilman,et al.  Diagnostic criteria for Parkinson disease. , 1999, Archives of neurology.

[98]  A. Lees,et al.  [123I]-FP-CIT-SPECT in the early diagnosis of PD presenting as exercise-induced dystonia , 2002, Neurology.

[99]  R. Felix,et al.  Combined 123I-FP-CIT and 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients , 2005, Journal of Neural Transmission.

[100]  E. Tolosa,et al.  Characteristics of idiopathic REM sleep behavior disorder and that associated with MSA and PD , 2005, Neurology.

[101]  D. Costa,et al.  Dementia with Lewy bodies versus Alzheimer's disease: Role of dopamine transporter imaging , 2003, Movement disorders : official journal of the Movement Disorder Society.

[102]  P. Acton,et al.  Comparison of region-of-interest analysis and human observers in the diagnosis of Parkinson's disease using [99mTc]TRODAT-1 and SPECT , 2004, IEEE Symposium Conference Record Nuclear Science 2004..

[103]  R. Wityk,et al.  Cardiac surgery and magnetic resonance imaging of the brain. , 2002, Archives of neurology.

[104]  A. Lees,et al.  Confirming Parkinson's disease with 123 I-FP-CIT SPECT , 1999 .

[105]  L. Thal,et al.  The Lewy body variant of Alzheimer's disease , 1990, Neurology.

[106]  M Laruelle,et al.  Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[107]  D J Wyper,et al.  Correlation of Parkinson's disease severity and duration with 123I‐FP‐CIT SPECT striatal uptake , 2000, Movement disorders : official journal of the Movement Disorder Society.

[108]  J. Gorman,et al.  Occupancy of dopamine D2 receptors by the atypical antipsychotic drugs risperidone and olanzapine: theoretical implications , 2003, Psychopharmacology.

[109]  Perry E Radau,et al.  Clinical testing of an optimized software solution for an automated, observer-independent evaluation of dopamine transporter SPECT studies. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[110]  D. Mash,et al.  Dopamine transporter messenger RNA in Parkinson's disease and control substantia nigra neurons , 1994, Annals of neurology.

[111]  C. Tanner,et al.  Levodopa and the progression of Parkinson's disease. , 2004, The New England journal of medicine.

[112]  H. Bracha,et al.  Asymmetry of neuroleptic-induced rigidity: Development of quantitative methods and clinical correlates , 1989, Psychiatry Research.